Form D · Pharmaceuticals
Slate Medicines, Inc.
Boston, MA · CIK 0002117806
Offering snapshot reported Mar 11, 2026 · SEC filing
- Reported sold
- $10M Offering amount: $130M
- Investors reported
- 6 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Feb 17, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 11, 2026 | Initial | $9,999,992 | No comparison | 6 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-576090
Offer and sale of Series A-1 and Series A-2 Preferred Stock (and the Common Stock issuable thereunder) and subsidiary shares exchangeable for Series A-1 Preferred Stock.
Source: Form D, filed Mar 11, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Neil Buckley | Director, Executive |
| Andrew Levin | Director |
| Tim Lohoff | Director |
| Gregory Frank Oakes | Executive |
| Sara Pacheco | Executive |
| Cindy Xiong | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
200 Berkeley Street, 18 Th Floor
Boston, MA, 02116
Phone: (617) 778-2500
Boston, MA, 02116
Phone: (617) 778-2500